Santen Pharmaceutical Co., Ltd. (SZD0)
Munich
10.40
0.00 (0.00%)
Real-time Data
06:00 AM
Day's Range
10.4010.40
52 wk Range
8.3011.80
Financial Statements - SZD0 - Santen Pharmaceutical Co., Ltd.
Revenue
291.62B▼ 2.8%
Net Income
37.56B▲ 4.8%Net Margin 12.9%
EBITDA
58.20B▼ 1.4%
Free Cash Flow
357.58M▼ 97.2%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 291.62B | 300B | 1.74B | 279.03B | 266.25B | 249.60B |
| Cost of Goods | 121.88B | 128.97B | 711.32M | 112.95B | 109.67B | 98.22B |
| Gross Profit | 169.74B | 171.02B | 1.03B | 166.08B | 156.58B | 151.38B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 47.79B | 46.88B | 222.41M | -3.09B | 35.88B | 12.18B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 47.44B | 47.48B | 172.40M | -5.79B | 35.61B | 11.68B |
| Income Tax | 9.88B | 11.62B | 18.30M | 9.18B | 8.42B | 2.56B |
| Net Income | 37.56B | 35.85B | 154.10M | -14.98B | 27.18B | 9.12B |
| EPS Basic | - | 103.98 | 72.59 | -38.6 | 68.07 | 23.3 |
| EPS Diluted | - | 103.68 | 72.37 | -38.6 | 67.97 | 23.26 |
| Basic Shares Outstanding | - | 348.68M | 2.11M | 387.42M | 63.13B | 63.08B |
| Diluted Shares Outstanding | - | 348.68M | 2.11M | 387.42M | 63.13B | 63.08B |
| Ebit | 49.43B | 50.19B | 187.78M | -4.30B | 36.82B | 13.17B |
| Ebitda | 58.20B | 59B | 292.68M | 12.94B | 53.88B | 30.67B |
| Net Income Continuous Operations | - | - | 154.10M | -14.98B | 27.18B | 9.12B |
| Minority Interests | -192M | 403M | -60M | 35M | 29M | 185M |
| Preferred Stock Dividends | 8M | 9M | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
